Attention-deficit and hyperactivity disorder (ADHD) is a common childhood disorder with a substantial genetic component. However, the extent to which epigenetic mechanisms play a role in the etiology of the disorder is not known. We performed epigenome-wide association studies (EWAS) within the Pregnancy And Childhood Epigenetics (PACE) Consortium to identify DNA methylation sites associated with ADHD symptoms at two methylation assessment periods: birth and school-age. We examined associations of DNA methylation in cord blood with repeatedly assessed ADHD symptoms (age range 4-15 years) in 2477 children from five cohorts and DNA methylation at school-age with concurrent ADHD symptoms (age 7-11 years) in 2374 children from ten cohorts. CpGs identified with nominal significance (p<0.05) in either of the EWAS were correlated between timepoints (ρ=0.30), suggesting overlap in associations, however, top signals were very different. At birth, we identified nine CpGs that were associated with later ADHD symptoms (P<1*10 -7 ), including ERC2 and CREB5. Peripheral blood DNA methylation at one of these CpGs (cg01271805 located in the promotor region of ERC2, which regulates neurotransmitter release) was previously associated with brain methylation. Another (cg25520701) lies within the gene body of CREB5, which was associated with neurite outgrowth and an ADHD diagnosis in previous studies. In contrast, at school-age, no CpGs were associated with ADHD with P<1*10-7. In conclusion, we found evidence in this study that DNA methylation at birth is associated with ADHD. Future studies are needed to confirm the utility of methylation variation as biomarker and its involvement in causal pathways.
Introduction
Attention-deficit and hyperactivity disorder (ADHD) is a common neurodevelopmental disorder characterized by impulsivity, excessive activity and attention problems. Symptoms often become apparent during school-age with a world-wide prevalence of 5-7.5%. 1 Genetic heritability is estimated between 64%-88%. 2, 3 Additionally several environmental factors are suspected to impact ADHD, e.g. prenatal maternal smoking or lead exposure. [4] [5] [6] [7] However, the genetics and environmental pathways contributing to ADHD risk remain unclear. Possibly, DNA methylation, an epigenetic mechanism regulating gene expression, may mediate genetic or environmental effects.
Several studies have investigated DNA methylation in relation to ADHD diagnoses or symptoms using candidate approaches or epigenome-wide association studies (EWAS) in peripheral blood and saliva tissue. 8, 9 A leading hypothesis concerning the etiology of ADHD suggests that deficiencies in the dopamine system of the brain impact ADHD development. 4, 10 Consequently, candidate studies have focused on genes related to dopamine function. For instance, DNA methylation alterations in DRD4 [11] [12] [13] , DRD5 12 , and DAT1 12, 14 genes have been associated with ADHD, though not consistently 15 . Beyond the candidate gene approach, three studies tested DNA methylation across the whole genome. One study performed an EWAS with saliva samples in school-aged children using a case-control design. 16 The study identified differentially methylated probes in VIPR2, a gene expressed in the caudate and previously associated with psychopathology.
Another EWAS investigated cord and peripheral blood DNA methylation at birth and at 7 years of age. 17 At birth, 13 probes located in SKI, ZNF544, ST3GAL3 and PEX2 were associated with ADHD trajectories from age 7 to 15 years, but the methylation status of these probes at age 7 was not associated with ADHD cross-sectionally. An EWAS in adults with ADHD failed to find any differentially methylated sites in peripheral blood. 18 Large multi-center epigenome-wide studies, which allow for increased power and generalizability, are lacking for childhood. Here we performed the first epigenome-wide prospective meta-analysis to identify DNA methylation sites associated with childhood ADHD symptoms in cohorts from the Pregnancy And Childhood Epigenetics (PACE) Consortium 19 . Since the temporal stability of methylation potentially associated with ADHD symptoms is unclear, we tested DNA methylation both at birth using cord blood and in school-age (age 7-9 years) using DNA derived from peripheral whole blood. In the analyses of cord blood methylation, the aim was to explain ADHD symptoms between ages 4 and 15 years. Many participating cohorts assessed ADHD repeatedly and we employed a repeated measures design to increase precision. Furthermore, we utilized data in childhood to examine cross-sectional DNA methylation patterns associated with ADHD symptoms at school age.
Materials and methods
This study comprises a birth methylation EWAS and a school-age methylation EWAS described successively below.
Birth Methylation EWAS Participants
Five cohorts (Avon Longitudinal Study of Parents and Children (ALSPAC), [20] [21] [22] Generation R (GENR), 23 INfancia y Medio Ambiente (INMA), 24 Newborn Epigenetic Study (NEST) 25, 26 and Prediction and prevention of preeclampsia and intrauterine growth restriction (PREDO) 27 ) in the PACE consortium had information on DNA methylation in cord blood and ADHD symptoms. These cohorts have a combined sample size of 2477 (Table 1) . Participants were mostly of European ancestry, except for NEST, an American cohort which also included participants of African ancestry. In NEST, separate EWAS were conducted for participants identifying as black or white to account for ancestry heterogeneity. See Supplementary Information 1 for full cohort descriptions.
DNA Methylation and QC
DNA methylation in cord blood was measured using the Illumina Infinium HumanMethylation450K BeadChip (Table S1 ). Methylation levels outside of the lower quartile minus 3*interquartile or upper quartile plus 3*interquartile range were removed.
Each cohort ran the EWAS separately according to a pre-specified harmonized analysis plan. The distribution of the regression estimates and p-values were examined for each cohort and pooled results. Deviations from a normal distribution of regression estimates or a higher number of low p-values than expected by chance may be signs of residual confounding, or the result of a true poly-epigenetic signal. To help in interpretation of the results, we used the BACON method. 28 BACON analyzes the distribution of regression coefficients and estimates an empirical null distribution. Results can then be compared against the empirical null, which already includes biases, rather than the theoretical null.
We excluded CpG probes, that were available in fewer than four cohorts, fewer than 1000 participants, and allosomal probes, due to the complex interpretation of dosage compensation.
ADHD Symptoms
ADHD symptoms were measured when children were 4-15 years old (depending on the cohort) with parent-rated instruments, specifically the Behavior Assessment System for Children (BASC), 29 Child Behavior Checklist (CBCL), 30, 31 Conners 32 and the Development and Well-Being Assessment (DAWBA) 33 (Table S2 ). If a cohort had measured ADHD symptoms repeatedly (3 cohorts), we used a mixed model (see statistical analysis). The repeated measure design increased the precision of the ADHD severity estimate and sample size, since missing data in an assessment can be handled with maximum likelihood. Given the variety of instruments used within and across cohorts, all ADHD scores were z-score standardized to enable meta-analysis.
Statistical analysis
Cohorts with repeated ADHD assessment were analyzed using linear mixed models, with z-scores of ADHD symptoms as the outcome and methylation (in betas, ranging from 0 (unmethylated) to 1 (methylated)) as the main predictor. Each CpG probe was analyzed separately and pooled p-values were adjusted for multiple correction using Bonferroni adjustment. We used a random intercept on the participant and batch level, to account for clustering due to repeated measures and batch effects. The following potential confounders were included as fixed effects: maternal age, educational level, smoking status (yes vs no during pregnancy), gestational age, sex, and estimated white blood cell proportions (Bakulski reference estimated with the Houseman method). 34 Mixed models were fitted using restricted maximum likelihood. We used R 35 with the lme4 36 package to estimate the models. Cohorts with a single ADHD assessment wave used a model without random effects or batch level only.
Meta-analysis was performed using the Han and Eskin random effects model. 37 This model does not assume that true effects are homogeneous between cohorts, however, it does assume that null effects are homogeneous. This modified version of the random effect model has comparable power to a fixed effects analysis, while better accounting for study heterogeneity, such as ancestry differences, in simulation studies. 37 Genome-wide significance was defined at the Bonferroni-adjustment threshold of p<1*10 -7 , suggestive significance at p<1*10 -5 , and nominal significance at p<0.05.
Follow-up analyses
We performed several look-ups of genome-wide significant probes. We used the BECon database 38 to check the correlation between peripheral and brain methylation levels in post-mortem tissue. To test genetic influence we interrogated the genome-wide significant probes in MeQTL 39 and twin heritability databases. 40 We also attempted to replicate genome-wide significant probes reported in a previous EWAS from the ALSPAC study. 17 For replication we reran the meta-analysis without the ALSPAC cohort. To quantify the variance explained by genome-wide significant probes, we predicted ADHD scores at age 8 in Generation R by all meta-analytically genome-wide significant probes. We applied 10-fold cross-validation with 100 repetitions to improve generalizability and reduce bias from Generation R, which was part of the discovery.
Pathway Analysis
Pathway enrichment analysis were performed with the missMethylpackage 41 on suggestive probes (P<1*10 -5 ). We used as references: gene ontology (GO), KEGG and curated gene sets (http://software.broadinstitute.org/gsea/msigdb/collections.jsp#C2) from the Broad Institute Molecular signatures database 42 . P-values were adjusted using the default procedures by the number of CpGs associated with each gene 43 and false discovery rate.
To test enrichment for regulatory features (gene relative position, CpG island relative position and blood chromatin states) we applied χ 2 tests. Enrichment tests were performed for all CpGs, hypo and hypermethylated CpGs separately. CpG annotation was performed with the IlluminaHumanMethylation450kanno.ilmn-12.hg19 R package. 44 Annotation to chromatin states was from the Roadmap Epigenomics Project (https://egg2.wustl.edu/roadmap/web_portal/). See Supplementary Information 2 for full description.
School-age methylation EWAS Participants
Nine cohorts (ALSPAC, GENR, HELIX 45 and GLAKU 46 ) with a combined sample size of 2374 joined the school-age methylation EWAS (Table 1 , Supplementary Information 1).
HELIX consists of six jointly analyzed sub-cohorts 45 All cohorts had participants of European ancestry, except HELIX, which also included participants with a Pakistani background living in the UK, which were treated as a separate cohort in the meta-analysis.
Fifty-three percent of participants in the school-age EWAS were also part of the birth EWAS.
DNA Methylation and QC
DNA methylation was measured at ages 7-12 in peripheral whole blood. The Illumina Infinium HumanMethylation450K BeadChip and Infinium MethylationEPIC Kit (GLAKU) were used to interrogate CpG probes. QC steps were identical to the birth methylation EWAS.
ADHD Symptoms
ADHD symptoms were measured at the same age as DNA methylation (age 7-11 years) with the parent-rated measures DAWBA and CBCL (Table S2 ). Only the assessment closest to the DNA methylation assessment age was analyzed.
Statistical analysis
The statistical model was similar to the model used in the birth methylation EWAS without participant level random effect. However, cell counts were estimated with the Houseman method using the Reinius reference. 47 . We also added assessment age as covariate. The meta-analysis methods were identical to the birth methylation EWAS.
Follow-up analyses
We did not perform follow-up analyses due low signal. However, we attempted to replicate six probes identified as suggestive in a previous case-control EWAS in schoolage. 16 
Results

Birth Cord Blood Methylation
EWAS Quality Check
Four out of the six cohorts showed larger number of low p-values than expected under the null, as indexed by high λ ( Table 1 ). BACON analysis suggested that the majority of the inflation was due to a true signal, as indicated by inflation values clearly lower than λ. To test the impact of sample size on λ, we restricted the GENR sample randomly to 900 and 1100 participants, resulting in 812 and 991 participants due to missing covariates. The lambdas were 0.96, 1.21, 1.51 for 812, 991, and 1191 participants. We thus conclude that the over-representation of low p-values is mostly due to sufficient power to detect associations at higher sample sizes.
The BACON analyses also indicated a trend towards positive/negative regression coefficients in some of the datasets, which might indicate confounding, e.g. by population stratification. To test this, we added principal components of ancestry in GENR and ALSPAC, but these did not meaningfully change results.
We conducted the meta-analysis under the assumption that any such biases will be corrected in the pooled analysis, since they were not homogeneous across cohorts.
Indeed, the pooled estimates did not show a trend towards positive or negative regression estimates (Median=+0.02), only an overrepresentation of low p-values (λ=1.86, Figure 1 ).
The BACON estimates for inflation suggested that these are mostly due to a true signal (Inflation=1.1).
Single Probe Analysis
After QC, 472,817 CpG sites remained for the meta-analysis. Results of the cord blood EWAS are shown in Figure 2 . Nine CpG sites showed genome-wide significance (p<1*10 -7 , Table 2 ). ADHD symptoms were between 0.16SD (SE=0.03) and 0.44SD (SE= 0.12) higher with 10% lower methylation at these probes. Eight probes out of nine that were available in the BECon database 38 are typically methylated in both whole blood and the brain (Figures 3, S1 and S2). A lookup in the BECon database revealed that the CpG site cg01271805 in the promoter region of gene ERC2 shows variable methylation in three brain regions (BA10, BA20, BA7). Importantly, methylation levels in the brain are moderately correlated with whole blood methylation (ρ=0.33-0.46) (Figure 3 ), suggesting that peripheral cg01271805 methylation levels are a useful marker for brain methylation levels. The other seven genome-wide significant probes showed less consistent correlations between blood and brain tissues and associated genes had less specificity for expression in the brain, based on GTEx 48 data. No SNP was associated with our nine top CpG probes when accounting for linkage disequilibrium according to the MeQTL database 39 . Furthermore, all nine probes had a twin heritability below 20% in a previous study (Table S3 ). 40 After adjusting for inflation and bias with BACON, only one CpG remained statistically significant (cg25520701, CREB5, ß =-3.54, SE = 0.66, p = 9.59*10 -8 ).
It should be noted, that the BACON adjusted p-values rely on statistics from the traditional random effects model. With the traditional model, only cg25520701, cg09762907 and cg22997238 remained genome-wide significant. Thus the difference in p-value is not solely the result of adjustment for the inflation, but also the use of more conservative tests.
In Generation R, the joint explained variance of ADHD scores at age 8 by the genomewide significant probes was 1.8% (R 2 from 10-fold repeated cross-validation).
Pathway Analysis
Two-hundred forty-nine probes showed suggestive (P<1*10 -5 ) associations and were annotated to 182 unique genes. In gene-based analyses no pathway survived multiple testing correction.
The 248 suggestive CpGs were enriched in intergenic regions. Of these, 
Replication of previous EWAS
We attempted to replicate findings for 13 CpGs, at which DNA methylation at birth was associated with ADHD trajectories. 17 However, no probe survived multiple-testing correction. (Table S4 ).
School-age methylation EWAS Quality Checks
The regression coefficient distribution showed no signs of errors, but three out of the five cohorts showed a trend towards positive associations in separate analyses ( Table   1 ). The lambda was below 1.11 for all cohorts. BACON suggested no inflation of the test statistics due to confounding or other biases, though the trend towards positive associations remained. The pooled results showed a low lambda (λ=0.96), no inflation (BACON inflation estimate = 0.92), but a slight over-representation of positive associations (BACON bias estimate = 0.14).
Single Probe Meta-Analysis
We associated DNA methylation at school-age in whole-blood at 466,574 CpG sites with ADHD symptoms at the same age. No CpG reached genome-wide significance (all p>4.96E-06, Figure 2 ). Furthermore, none of the loci at which DNA methylation at birth was significantly associated with ADHD symptoms, also showed a cross-sectional association at school-age (p>0.33).
Replication of previous EWAS
We attempted to replicate the six most suggestive EWAS CpGs of a previous casecontrol study. 16 While all but one showed a consistent direction, none of the CpGs were statistically significant. (Table S5 )
Stability of methylation association across age
The associations between methylation at birth with ADHD symptoms and methylation at school-age with ADHD symptoms were largely consistent for nominally significant probes. The regression estimates from CpG sites, with nominally significant associations at birth (p<0.05, n=73,057) correlated with the regression estimates of the school-age EWAS (ρ=0.45). When restricting the school-age methylation EWAS to those cohorts, which were not featured in the birth methylation EWAS (thus excluding overlaps), the correlation remained (ρ=0.30). Vice versa, when filtering for probes which were nominally significant at school-age, 23,770 probes remained of which 4075 overlapped with nominally significant probes at birth. The correlation for this set was very similar, ρ=0.47 among all cohorts and ρ=0.35 between independent cohorts.
Discussion
In this population-based study, we performed the first epigenome-wide metaanalysis of ADHD symptoms in childhood, using two DNA methylation assessments (birth and school-age), as well as repeated measures of ADHD symptoms. DNA methylation at birth, but not at school-age, was associated with later development of ADHD symptoms with genome-wide significance at nine loci. Interestingly, the identified probes showed a pattern of a high average rate of methylation in cord blood, while lower levels of methylation were associated with more ADHD symptoms in childhood. DNA methylation in cord blood reflects the effects of genetics and the intrauterine environment. The results suggest that cord blood DNA methylation is a marker for some of the ADHD risk factors before birth or functions as a potential mediator of these risk factors. While not impossible, reverse causality at this age is unlikely to explain our results, as ADHD only manifests at later stages of development.
We analyzed DNA methylation in cord and peripheral blood, which may not correspond to the methylation status in the brain. DNA methylation in the brain arguably has the strongest a priori likelihood of representing causal mechanisms. Seven out of eight significant probes did not show consistent correlation between methylation status in whole blood and post-mortem brain tissue in a previous study, i.e. DNA methylation levels in blood may not represent brain levels and thus associations with ADHD may be different. 38 However, methylation levels of cg01271805 in whole blood are associated with methylation levels in various brain regions. Importantly, this probe lies in the promoter region of the gene ERC2, that is highly expressed in brain tissue. ERC2 regulates calcium dependent neurotransmitter release in the axonal terminal. 49 Specifically, ERC2 is suspected to increase the sensitivity of voltage dependent calcium channels to hyperpolarization, resulting in higher neurotransmitter release. SNPs in the ERC2 locus have been suggested to distinguish schizophrenia and bipolar disorder patients 50 and to impact cognitive functioning 51 . ERC2 is especially expressed in Broadmann area 9 of the frontal cortex. 48 Previous imaging studies have demonstrated differential activation in this area when children with or without ADHD performed various cognitive tasks. 52, 53 The correlation with brain methylation, the location in a promoter and gene expression in the brain make cg01271805 a plausible candidate locus, where reduced methylation may be mechanistically involved in ADHD development. We hypothesize, that lower methylation levels at cg01271805 increases the expression of ERC2, which in turn increases neurotransmitter release, with an adverse impact on the development of ADHD symptoms.
Another gene with a genome-wide significant probe and high relevance for neural functioning is CREB5 (cg25520701). CREB5 is expressed in fetal brain and the prefrontal cortex, and has been previously related to neurite outgrowth. Moreover, SNPs in this gene were associated with ADHD in two recent GWAS. 54, 55 Thus, it is plausible that differences in DNA methylation at this locus may modify ADHD risk during development.
While the birth methylation EWAS identified several loci, associating school-age methylation with concurrent ADHD symptoms revealed no genome-wide significant associations. Furthermore, the overall association signal was lower, despite similar sample sizes. None of the probes, which were significantly associated at birth showed any association when measured at school-age. Given that sample sizes were comparable, this difference must come from changes in the epigenome or study heterogeneity, rather than differences in statistical power. In terms of instrument heterogeneity, the school-age EWAS was more homogeneous, almost exclusively using CBCL. Additionally, as both EWAS feature a mix of several cohorts selected based on the same criteria and around half of the participants were represented at both time points, study heterogeneity appears to be an unlikely explanation. The stronger signal in the birth EWAS may be considered surprising given that typically two measures are typically more strongly associated if measured in closer temporal proximity. However, in line with our results Walton et al. also observed in a previous EWAS, 17 that birth methylation may be a better predictor of later ADHD symptoms than childhood methylation, possibly reflecting sensitive periods. Whether DNA methylation in cord blood has stronger causal effects or is a better marker for early life factors cannot be concluded from the present study. Alternatively, tissue differences between cord blood and whole blood may account for the differences in association pattern. Finally, it is possible that interventions in childhood and other environmental influences reduced the initial epigenetic differences at birth between children with higher and lower ADHD symptoms. Yet, we observed consistency in the associations of methylation at both timepoints with ADHD symptoms. The regression estimates of both EWAS correlated on a genome-wide level.
Strengths of this study include the large sample size, repeated outcome measures, Spanish Institute of Health Carlos III extensive control for potential confounders and the use of DNA methylation at two different time-points, enabling us to characterize both prospective and cross-sectional associations with ADHD symptoms. However, several limitations need to be discussed as well. A causal interpretation of our findings is challenged by the possibility of residual confounding and reverse causality. DNA methylation might be a marker for untested adverse environmental factors that could affect ADHD via independent pathways. In addition, children with higher ADHD symptoms may evoke a particular environment, which might shape the epigenome. Larger sample sizes are necessary to detect further methylation sites. As is typical for (epi-)genetic studies, the effect size of individual top probes was rather small: the joint effect of the genome-wide probes was estimated below 2%. However, the strong genome-wide epigenetic signal suggests a potential for the development of epigenetic-scores based on birth methylation, which could lead to early prevention efforts before ADHD symptoms arise.
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